| Name | Title | Contact Details |
|---|
Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.
Roche NimbleGen, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Diazyme is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.